• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Exploring Novel Options for the Management of Uncomplicated UTIs

Opinion
Video

Panelists discuss how sulopenem etzadroxil/probenecid, approved in October 2024, functions as an oral β-lactam/β-lactamase inhibitor effective against extended-spectrum β-lactamase producers per SURE 1 and REASSURE trial findings whereas gepotidacin works through a novel mechanism as a triazaacenaphthylene bacterial topoisomerase inhibitor targeting resistant pathogens via unique DNA gyrase and topoisomerase IV binding sites, with EAGLE trial findings demonstrating noninferiority to nitrofurantoin with approximately 90% cure rates.

Video content above is prompted by the following:

  • In October 2024, sulopenem etzadroxil/probenecid received FDA approval for uncomplicated urinary tract infection (UTI) based on the SURE 1 and REASSURE data. What is the mechanism of action of this therapy, and what are some key efficacy and safety points to be shared?
  • Another emerging therapy showing promise in addressing patients with recurrent UTIs is gepotidacin, based on the EAGLE-2 and EAGLE-3trial findings. How is gepotidacin’s mechanism of action different from the other 2 newly approved therapies?

What are some key points to share regarding the methodology and outcomes of the EAGLE trials?

Related Videos
Dr Sundar Jagannath
Dr Muhammad Faizan
Andrew Kuykendall, MD, Moffitt Cancer Center
Dr Sundar Jagannath
4 experts in this video
4 experts in this video
Screenshot of a webinar panel discussion with Viet Le, PA-C; Nathan Wong, PhD, MPH; Alison Bailey, MD; and Martha Gulati, MD, MS
World Hepatitis Day graphic | Image Credit: uazzal - stock.adobe.com
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.